FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Reject Cipla NDA for Descovy Duplicate: Gilead

[ Price : $8.95]

Gilead calls on FDA to rescind its decision to file a Cipla 505(b)(2) NDA for an apparent duplicate of Gileads Descovy.

Warning Letter to Firm Over Weight-loss/Diabetes Drugs

[ Price : $8.95]

FDA issues a Warning Letter to New Life Pharma citing serious manufacturing and regulatory violations tied to the companys product...

FDA extends review for Sanofis subcutaneous Sarclisa

[ Price : $8.95]

FDA extends by three months its review of a Sanofi BLA for a subcutaneous formulation of Sarclisa (isatuximab-irfc) for use in com...

UCSF Radiopharmaceutical Facility CGMP Issues

[ Price : $8.95]

FDA warns the University of California at San Francisco radiopharmaceutical facility about CGMP violations in its production of fi...

CGMP Violations at Par Health USA/Endo USA

[ Price : $8.95]

FDA warns Par USA/Endo USA about CGMP violations in its manufacturing of finished drugs.

Multiple Violations at Chinas Xiamen Kang

[ Price : $8.95]

FDA warns Chinas Xiamen Kang Zhongyuan Biotechnology Co. about producing drugs in insanitary conditions and making misleading or d...

New FDA AEMS Dashboard Needs Context, Transparency: Professors

[ Price : $8.95]

Two pharmacy professors say FDA needs to solicit expert and client input on its new Adverse Event Monitoring System dashboard and ...

FDA Accepts Roche sBLA for Gazyva in Lupus

[ Price : $8.95]

FDA accepts a Roche supplemental BLA that seeks to expand use of Gazyva to treat Systemic Lupus Erythematosus.

Makary Support Vouchers for Psychedelic Therapies

[ Price : $8.95]

FDA commissioner Marty Makary tells Fox Business that the agency will deploy its new national priority voucher program to signific...

FDA Approves Mercks Idvynso for Treating HIV

[ Price : $8.95]

FDA approves Mercks Idvynso, a once-daily, single-tablet regimen for adults with HIV-1 who are already virologically suppressed.